Dermatology Times
FEBRUARY 19, 2024
Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.
Dermatology Times
MAY 16, 2024
Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.
Dermatology Times
SEPTEMBER 26, 2023
Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.
The Dermatology Digest
FEBRUARY 8, 2024
The Dermatology Digest asked key thought leaders and editorial advisory board members to take out their crystal balls and weigh in on what’s to come in 2024 and beyond. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” We will, for sure, have new medications for chronic urticaria.”
The Dermatology Digest
MAY 17, 2024
Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)
Dermatology Times
JANUARY 9, 2024
Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.
Dermatology Times
AUGUST 8, 2024
Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.
Expert insights. Personalized for you.
77 
Let's personalize your content